Net sales decreased 6% to $992m in the fourth quarter of 2010.
Specialty Injectable Pharmaceuticals sales were stable despite the year-over-year impact of the temporary discontinuation of US sales of the oncolytic oxaliplatin.
However, the Medication Management declined, primarily due to the company’s voluntary hold on shipments of its Symbiq Infusion System to new customers. Other Pharma also declined mainly because of the impact of non-strategic asset divestitures.
For the full-year 2010 the company achieved net sales of $3.9bn, and adjusted diluted earnings per share of $3.31.
Hospira expects net sales growth for full-year 2011 to be approximately 5 to 7% on a constant-currency basis, and foreign exchange to provide a positive contribution of approximately one percent, based on current exchange rates.
The net sales projections assume US launches during 2011 of two oncolytics, docetaxel and a solution presentation of gemcitabine.